KR20240049337A - Gdf15 융합 단백질 및 이의 용도 - Google Patents
Gdf15 융합 단백질 및 이의 용도 Download PDFInfo
- Publication number
- KR20240049337A KR20240049337A KR1020247009488A KR20247009488A KR20240049337A KR 20240049337 A KR20240049337 A KR 20240049337A KR 1020247009488 A KR1020247009488 A KR 1020247009488A KR 20247009488 A KR20247009488 A KR 20247009488A KR 20240049337 A KR20240049337 A KR 20240049337A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- fusion protein
- amino acid
- gdf15
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110977378.7 | 2021-08-24 | ||
| CN202110977378 | 2021-08-24 | ||
| PCT/CN2022/114096 WO2023025120A1 (en) | 2021-08-24 | 2022-08-23 | Gdf15 fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240049337A true KR20240049337A (ko) | 2024-04-16 |
Family
ID=85321545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247009488A Pending KR20240049337A (ko) | 2021-08-24 | 2022-08-23 | Gdf15 융합 단백질 및 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20240350588A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4393941A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532882A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240049337A (cg-RX-API-DMAC7.html) |
| CN (3) | CN115925982A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022333099A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226178A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2023025120A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101374454B1 (ko) * | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| CN105102618B (zh) * | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| EP3027647A4 (en) * | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| LT3027642T (lt) * | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20210080460A (ko) * | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
| BR112021021271A2 (pt) * | 2019-04-23 | 2021-12-21 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15 |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| EP4458863A1 (en) * | 2021-12-31 | 2024-11-06 | Sunshine Lake Pharma Co., Ltd. | Fusion protein of glp-1 and gdf15 and use thereof |
-
2022
- 2022-08-23 US US18/682,002 patent/US20240350588A1/en active Pending
- 2022-08-23 WO PCT/CN2022/114096 patent/WO2023025120A1/en not_active Ceased
- 2022-08-23 CN CN202211012820.3A patent/CN115925982A/zh active Pending
- 2022-08-23 US US18/685,702 patent/US20240391971A1/en active Pending
- 2022-08-23 KR KR1020247009488A patent/KR20240049337A/ko active Pending
- 2022-08-23 CN CN202211013315.0A patent/CN115925984A/zh active Pending
- 2022-08-23 US US18/294,397 patent/US20240343770A1/en active Pending
- 2022-08-23 CN CN202211012940.3A patent/CN115925983A/zh active Pending
- 2022-08-23 AU AU2022333099A patent/AU2022333099A1/en active Pending
- 2022-08-23 EP EP22860469.0A patent/EP4393941A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114130 patent/WO2023025123A1/zh not_active Ceased
- 2022-08-23 CA CA3226178A patent/CA3226178A1/en active Pending
- 2022-08-23 EP EP22860466.6A patent/EP4392461A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114143 patent/WO2023025129A1/zh not_active Ceased
- 2022-08-23 JP JP2024512156A patent/JP2024532882A/ja active Pending
- 2022-08-23 EP EP22860475.7A patent/EP4393940A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240350588A1 (en) | 2024-10-24 |
| EP4393941A4 (en) | 2025-10-15 |
| AU2022333099A1 (en) | 2024-02-08 |
| CN115925982A (zh) | 2023-04-07 |
| CA3226178A1 (en) | 2023-03-02 |
| EP4393941A1 (en) | 2024-07-03 |
| WO2023025120A1 (en) | 2023-03-02 |
| JP2024532882A (ja) | 2024-09-10 |
| CN115925983A (zh) | 2023-04-07 |
| CN115925984A (zh) | 2023-04-07 |
| EP4393940A1 (en) | 2024-07-03 |
| WO2023025129A1 (zh) | 2023-03-02 |
| EP4392461A4 (en) | 2025-10-15 |
| EP4393940A4 (en) | 2025-10-15 |
| US20240391971A1 (en) | 2024-11-28 |
| EP4392461A1 (en) | 2024-07-03 |
| WO2023025123A1 (zh) | 2023-03-02 |
| US20240343770A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| EP3144320B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| KR102668200B1 (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| JP2020509761A (ja) | 免疫グロブリンのFc部分を含む二重標的融合タンパク質 | |
| JP7064618B2 (ja) | 増殖分化因子15アゴニスト化合物およびその使用方法 | |
| US20220017584A1 (en) | Growth differentiation factor 15 fusion proteins | |
| WO2018032787A1 (zh) | 高糖基化人生长激素融合蛋白及其制备方法与用途 | |
| CN114591415B (zh) | Glp-1/gcg双受体激动剂多肽及其融合蛋白 | |
| WO2023280133A1 (zh) | 融合蛋白及其应用 | |
| TWI889865B (zh) | 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途 | |
| CN116568711A (zh) | 一种人glp-1多肽变体及其应用 | |
| KR20240126875A (ko) | Glp-1과 gdf15의 융합 단백질 및 이의 용도 | |
| WO2023025120A1 (en) | Gdf15 fusion proteins and uses thereof | |
| US20230072260A1 (en) | Insulin-fc fusion proteins and methods of use to treat cancer | |
| WO2026039359A1 (en) | Fc fusion protein therapeutics for companion animal obesity and methods of use | |
| WO2026039340A1 (en) | Fc fusion protein therapeutics for companion animal obesity and methods of use | |
| WO2026039341A1 (en) | Fc fusion protein therapeutics for companion animal obesity and methods of use | |
| US20090270325A1 (en) | Growth factor | |
| HK1045160A (en) | Expression and export of anti-obesity proteins as fc fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |